Abstract
OBJECTIVES: Redo surgical aortic valve replacement (rSAVR) poses challenges, particularly in anchoring a new prosthesis within a deteriorated annulus. While rapid deployment (RD) SAVR is not recommended for redo cases, we retrospectively analysed its potential expanded indication. The primary objective was to examine the potential expanded indication of RD rSAVR and the advantages it might confer, particularly in surgeries with prolonged intraoperative times. METHODS: Between January 2014 and March 2022, 37 patients underwent RD rSAVR (Edwards Intuity Elite rapid deployment valve system (Edwards Lifesciences, Irvine, CA)) due to structural valve degeneration, compared with 48 patients undergoing conventional rSAVR (crSAVR) for aortic stenosis. Data were collected retrospectively after gaining patient consent. RESULTS: No significant difference in postoperative or intraoperative complications was obtained, no repeat surgery was performed due to valvular complications in either group, and only 1 paravalvular leak was noted in the crSAVR group. A very low new pacemaker rate was observed in both the groups (3% RD rSAVR vs 6% crSAVR). The cardiopulmonary bypass (CPB) and cross-clamping time is significantly lower in the RD rSAVR collective, which is reflected in the pure rSAVR after stratification according to concomitant procedures. On average, a 23 mm valve was selected in both the groups with comparable postoperative mean gradient. The RD group had a higher TIA rate (19% vs 0%, P = .002), though without residual neurological deficits, but no significant differences in postoperative stroke, respiratory complications, or mortality. CONCLUSIONS: RD rSAVR appears safe in redo settings, providing excellent haemodynamic results and time efficiency in experienced hands.